O R N Remedies Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 19 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.92 M
- Satisfied Charges ₹ 2.50 M
- Revenue Growth 2.03%
- Profit Growth 19.82%
- Ebitda 84.78%
- Net Worth 101.12%
- Total Assets -0.39%
About O R N Remedies
O R N Remedies Private Limited (ORNRPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 September 2005 and has a history of 19 years and five months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹3.92 M. The company has closed loans amounting to ₹2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Anand Aggarwal and Ashish Aggarwal serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U00304DL2005PTC140854
- Company No.
140854
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Sep 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at O R N Remedies?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anand Aggarwal  | Director | 16-Sep-2005 | Current |
| Ashish Aggarwal | Director | 06-Oct-2005 | Current |
Financial Performance of O R N Remedies.
O R N Remedies Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 2.03% increase. The company also saw a substantial improvement in profitability, with a 19.82% increase in profit. The company's net worth Soared by an impressive increase of 101.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of O R N Remedies?
In 2020, O R N Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹3.92 M
₹2.50 M
Charges Breakdown by Lending Institutions
- Others : 0.24 Cr
- Canara Bank : 0.15 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Jul 2023 | Canara Bank | ₹1.50 M | Open |
| 29 Aug 2020 | Others | ₹2.42 M | Open |
| 13 Aug 2013 | Others | ₹2.00 M | Satisfied |
| 26 Feb 2008 | Dena Bank | ₹0.50 M | Satisfied |
How Many Employees Work at O R N Remedies?
Unlock and access historical data on people associated with O R N Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of O R N Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped O R N Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
